All In Biotech

Drug Trial Radar · NCT02791763

Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

A 52-week, Phase III, Open-label, Multi-center Study to Evaluate Efficacy and Safety of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

355

Actual

Start

Jun 6, 2016

Primary completion

Oct 26, 2018

Study completion Oct 26, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 286 Japanese ND and 50 PD subjects with renal anemia. The study will consist of three cohorts. Cohort 1 and Cohort 3 will consist of ND subjects (Erythropoiesis-Stimulating Agent \[ESA\] users and ESA non-users) randomized to receive GSK1278863 or epoetin beta pegol in a ratio of 1:1. PD subjects will be enrolled into Cohort 2 and will receive GSK1278863. This study consists of a 4-week screening phase, a 52-week treatment phase (including primary efficacy evaluation period \[Weeks 40 to 52\]), and a 4-week follow-up phase following the treatment phase. The primary objective of this study is to demonstrate non-inferiority of GSK1278863 to epoetin beta pegol based on mean hemoglobin (Hgb) during the primary efficacy evaluation period in ND subjects. ESA non-users from Cohort 1 will be excluded from the primary efficacy analysis. Study results will be used as pivotal study data for an NDA submitted for GSK1278863 for the treatment of renal anemia in Japan.

Conditions

  • Anaemia

Interventions

  • 1 to 4 mg tablets of GSK1278863Drug

    7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.

  • 6 mg GSK1278863 tabletDrug

    9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.

  • Epoetin beta pegolDrug

    An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND ParticipantsTime frame: Weeks 40 to 52

Locations

56 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Ehime, Japan

  • GSK Investigational Site

    Fukui, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Gifu, Japan

  • GSK Investigational Site

    Gifu, Japan

  • GSK Investigational Site

    Hiroshima, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ishikawa, Japan

  • GSK Investigational Site

    Ishikawa, Japan

  • GSK Investigational Site

    Kagoshima, Japan

  • GSK Investigational Site

    Kagoshima, Japan

  • GSK Investigational Site

    Kagoshima, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kumamoto, Japan

  • GSK Investigational Site

    Kumamoto, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Numakunai, Japan

  • GSK Investigational Site

    Ōita, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.